meningococcal A C Y and W-135 diphtheria conjugate vaccine

Action and Spectrum

Actions and Spectrum: 

Actions: 

meningococcal A C Y and W-135 diphtheria conjugate vaccine  in which meningococcal serogroup A, C, Y and W-135 polysaccharide antigens is conjugated to diphtheria toxoid protein carrier which induces bacterial antibody production that gives protection against meningococcal disease. 

Spectrum: 

Indicated for the prevevntion against invasive meningococcal disease and also as a booster dose for the indivaiduals who are at high risk for contracting infection again after primary vaccination. 

Drug Interaction

Adverse Reaction

Frequency defined 

>10% 

Menveo 

• 7-9 months 

• Erythema >50 mm (15%) 
• Tenderness, severe (11%) 

• 12 months 

• Erythema >50 mm (13%) 

• 2-5 years 

• Injection site pain, any (33%) 
• Erythema, any (27%) 
• Irritability, any (21%) 
• Induration, any (18%) 
• Sleepiness, any (16%) 

• 6-10 years 

• Injection site pain (39%) 
• Erythema (28%) 
• Headache (18%) 
• Induration (17%) 
• Malaise (14%) 

Menactra 

• 2-5 years 

• Injection site pain, any (35%) 
• Erythema, any (25%) 
• Irritability, any (22%) 
• Induration, any (18%) 
• Sleepiness, any (18%) 

• 6-10 years 

• Injection site pain, any (45%) 
• Erythema, any (22%) 
• Induration, any (13%) 
• Headache, any (13%) 
• Malaise, any (11%) 

1-10% 

Menveo 

• 7-9 months 

• Induration >50 mm (ages 7-9 months) (8%) 

• 12 months 

• Tenderness, severe (10%) 
• Induration >50 mm (8%) 

• 2-5 years 

• Change in eating, any (9%) 
• Diarrhea, any (7%) 
• Injection site pain, moderate (6%) 
• Irritability, moderate (6%) 
• Erythema, moderate (5%) 
• Headache, any (5%) 
• Rash, any (4%) 
• Sleepiness, moderate (3%) 
• Induration, moderate (2%) 
• Fever, any (2%) 
• Injection site pain, severe (1%) 
• Erythema, severe (1%) 
• Irritability, severe (1%) 
• Sleepiness, severe (1%) 
• Change in eating, severe (1%) 
• Diarrhea, moderate (1%) 
• Headache, moderate (1%) 
• Arthralgia, moderate (1%) 
• Vomiting, moderate (1%) 

• 6-10 years 

• Myalgia, any (10%) 
• Nausea, any (8%) 
• Arthralgia, any (6%) 
• Chills, any (5%) 
• Rash, any (5%) 
• Headache, moderate (3%) 
• Malaise, moderate (3%) 
• Myalgia, moderate (2%) 
• Nausea, moderate (2%) 
• Fever, any (2%) 
• Headache, severe (1%) 
• Malaise, severe (1%) 
• Myalgia, severe (1%) 
• Nausea, severe (1%) 
• Arthralgia, moderate (1%) 
• Chills, moderate (1%) 
• Fever, moderate (1%) 

Menactra 

• 2-5 years 

• Change in eating, any (10%) 
• Injection site pain, moderate (8%) 
• Diarrhea, any (8%) 
• Irritability, moderate (7%) 
• Headache, any (6%) 
• Sleepiness, moderate (5%) 
• Rash, any (5%) 
• Erythema, moderate (3%) 
• Induration, moderate (2%) 
• Change in eating, moderate (2%) 
• Fever, any (2%) 
• Irritability, severe (1%) 
• Sleepiness, severe (1%) 
• Diarrhea, moderate (1%) 
• Headache, moderate (1%) 
• Arthralgia, moderate (1%) 
• Vomiting, moderate (1%) 

• 6-10 years 

• Myalgia, any (10%) 
• Injection site pain, any (10%) 
• Nausea, any (6%) 
• Chills, any (5%) 
• Arthralgia, any (4%) 
• Rash, any (3%) 
• Malaise, moderate (3%) 
• Injection site pain, severe (2%) 
• Erythema, moderate (2%) 
• Induration, moderate (2%) 
• Headache, moderate (2%) 
• Myalgia, moderate (2%) 
• Nausea, moderate (2%) 
• Headache, severe (1%) 
• Malaise, severe (1%) 
• Myalgia, severe (1%) 
• Arthralgia, moderate (1%) 
• Chills, moderate (1%) 

<1% 

Menveo 

• 2-5 years 

• Induration, severe (0.4%) 
• Fever, moderate (0.4%) 
• Diarrhea, severe (0.1%) 
• Arthralgia, severe (0.1%) 
• Vomiting, severe (0.1%) 

Menactra 

• 2-5 years 

• Injection site pain, severe (0.4%) 
• Erythema, severe (0.3%) 
• Induration, severe (0.3%) 
• Change in eating, severe (0.3%) 
• Headache, severe (0.3%) 
• Fever, moderate (0.3%) 

• 6-10 years 

• Nausea, severe (0.4%) 
• Arthralgia, severe (0.4%) 
• Chills, severe (0.4%) 
• Fever, severe (0.4%) 
• Erythema, severe (0.2%) 

Black Box Warning

Black Box Warning: 

Kept out of reach of children. This vaccine should be administered only via IM route.

Contraindication / Caution

Contraindication/Caution: 

Contraindications 

• Allergic reactions 

Cautions 

• Acute allergic reactions 
• Syncope 
• Guillian-Barre syndrome 
• Immunosuppressive treatment 
• Coadministration with other vaccines 
• Altered immunocompetence 
• Apnea 

Pregnancy / Lactation

Pregnancy consideration:  

No data is available regarding the administration of the drug during pregnancy. 

Breastfeeding warnings:  

No data is available regarding the excretion of drug in breast milk. 

Pregnancy category: 

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester. 

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. 

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.    

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.    

Category N: No data is available for the drug under this category. 

Pharmacology

Pharmacology: 

meningococcal A C Y and W-135 diphtheria conjugate vaccine in which meningococcal serogroup A, C, Y and W-135 polysaccharide antigens is conjugated to diphtheria toxoid protein carrier which induces bacterial antibody production that gives protection against meningococcal disease. 

Pharmacodynamics: 

meningococcal A C Y and W-135 diphtheria conjugate vaccine in which meningococcal serogroup A, C, Y and W-135 polysaccharide antigens is conjugated to diphtheria toxoid protein carrier which induces bacterial antibody production that gives protection against meningococcal disease. This vaccine shows 4-fold increase in bactericidal antibodies which are effective against meningococcal disease. 

Pharmacokinetics: 

Limited data available. Onset of action post vaccination occurs via seroconversion is after 1 month where duration of its action that is antibody waning can see upto 5 years following primary vaccination where booster dose is recommended to make antibodies persist in the body and this antibody waning may vary with special product and among serogroups. 

Adminstartion

Administration: 

meningococcal A C Y and W-135 diphtheria conjugate vaccine is carried out its immunization by intramuscular route only. Injection site recommended in infants is anterolateral aspect of thigh and after 12 months children the injection site can also be deltoid muscle. 

Patient Information Leaflet

Patient information leaflet 

Generic Name: meningococcal A C Y and W-135 diphtheria conjugate vaccine 

Pronounced: muh-nin-jeh-KOK-ul  A-C-Y and -W-135 dif-THEER-ee-uh kun-juh-gayt vak-seen 

Why do we use meningococcal A C Y and W-135 diphtheria conjugate vaccine? 

meningococcal A C Y and W-135 diphtheria conjugate vaccine is used in the immunization via IM injection to give protection against meningococcal disease that is caused due to Neisseria meningitidis. This can also be used as a booster dose after primary vaccination after 10 years of age or above 12 years of age administered to the persons with high risk.